Gaurav Syal
YOU?
Author Swipe
View article: Cost Effectiveness of the 8-Strain Probiotic in Primary and Secondary Prophylaxis of Pouchitis
Cost Effectiveness of the 8-Strain Probiotic in Primary and Secondary Prophylaxis of Pouchitis Open
Compared to no prophylaxis, the 8-strain probiotic is not cost-effective for primary prevention of pouchitis. It is cost-effective for secondary prophylaxis of frequent pouchitis but not for secondary prophylaxis of infrequent pouchitis.
View article: Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis Open
View article: Communicating Information Regarding IBD Remission to Patients: Evidence From a Survey of Adult Patients in the United States
Communicating Information Regarding IBD Remission to Patients: Evidence From a Survey of Adult Patients in the United States Open
Background Previous research suggests patients living with inflammatory bowel disease (IBD) understand IBD remission differently than healthcare professionals, which could influence patient expectations and clinical outcomes. We investigat…
View article: Ileal Paneth Cell Phenotype is a Cellular Biomarker for Pouch Complications in Ulcerative Colitis
Ileal Paneth Cell Phenotype is a Cellular Biomarker for Pouch Complications in Ulcerative Colitis Open
Background and Aims Biomarkers that integrate genetic and environmental factors and predict outcome in complex immune diseases such as inflammatory bowel disease (IBD; including Crohn’s disease [CD] and ulcerative colitis [UC]) are needed.…
View article: Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn’s disease
Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn’s disease Open
BACKGROUND Evidence suggests inflammatory mesenteric fat is involved in post-operative recurrence (POR) of Crohn’s disease (CD). However, its prognostic value is uncertain, in part, due to difficulties studying it non-invasively. AIM To ev…
View article: IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN’S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY
IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN’S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY Open
BACKGROUND AND AIMS Treatment efficacy and safety are primary factors in choosing therapies in patients with Crohn’s disease (CD). However, they can be perceived to be at odds with each other with more potent therapies associated with incr…
View article: AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders
AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Open
View article: Patients’ Perspectives, Experiences, and Concerns With Perianal Fistulae: Insights From Online Targeted-Disease Forums
Patients’ Perspectives, Experiences, and Concerns With Perianal Fistulae: Insights From Online Targeted-Disease Forums Open
Background Perianal fistulae can undermine physical, emotional, and social well-being in patients with Crohn’s disease and are challenging to manage. Social media offers a rich opportunity to gain an in-depth understanding of the impact of…
View article: Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn’s disease and leads to impaired CFB cleavage and phagocytosis
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn’s disease and leads to impaired CFB cleavage and phagocytosis Open
Objective Perianal Crohn’s disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We performed a genetic association study comparing C…
View article: Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study
Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study Open
View article: Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial
Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial Open
INTRODUCTION: To support shared decision-making (SDM) between patients and providers surrounding biologic treatments, we created IBD&me (ibdandme.org)—a freely available, unbranded, interactive decision aid. We performed a multicenter comp…
View article: Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study Open
View article: 653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION Open
View article: 656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE Open
View article: PATIENTS’ PERSPECTIVES, EXPERIENCES, AND CONCERNS WITH CROHN’S PERIANAL FISTULAE: INSIGHTS FROM SOCIAL MEDIA PLATFORMS
PATIENTS’ PERSPECTIVES, EXPERIENCES, AND CONCERNS WITH CROHN’S PERIANAL FISTULAE: INSIGHTS FROM SOCIAL MEDIA PLATFORMS Open
INTRODUCTION Crohn’s perianal fistulae (CPF) impact the physical, emotional, and social wellbeing of patients. Despite the high biopsychosocial burden of CPF, limited data exist regarding how patients navigate challenges associated with th…
View article: PATIENTS' PERSPECTIVES, EXPERIENCES, AND CONCERNS WITH CROHN'S PERIANAL FISTULAE: INSIGHTS FROM SOCIAL MEDIA PLATFORMS
PATIENTS' PERSPECTIVES, EXPERIENCES, AND CONCERNS WITH CROHN'S PERIANAL FISTULAE: INSIGHTS FROM SOCIAL MEDIA PLATFORMS Open
View article: Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease
Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease Open
View article: Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease
Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease Open
Background and Aims In order to provide high-quality care, providers need to understand their patients’ goals and concerns. This study aims to identify and predict the goals and concerns prioritised by patients with inflammatory bowel dise…
View article: Health Maintenance Consensus for Adults With Inflammatory Bowel Disease
Health Maintenance Consensus for Adults With Inflammatory Bowel Disease Open
Background With the management of inflammatory bowel disease (IBD) becoming increasingly complex, incorporating preventive care health maintenance measures can be challenging. The aim of developing these updated recommendations is to provi…
View article: Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium
Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium Open
View article: Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis Open
View article: Disease and Treatment Patterns among Patients with Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States
Disease and Treatment Patterns among Patients with Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States Open
Background: Gaps exist in our understanding of the clinical course of pouch-related disorders. Methods: We evaluated baseline disease activity and longitudinal treatment patterns among patients with inflammatory conditions of the pouch. Re…
P120 PRE-POUCH ILEITIS IS A RISK FACTOR FOR DEVELOPMENT OF CROHN’S DISEASE-LIKE COMPLICATIONS, NEED FOR BIOLOGIC THERAPY AND POUCH FAILURE Open
28 QUALITY OF CARE INITIATIVE IMPROVES OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE Open
View article: Is It Time For High Dose Influenza Vaccination In Inflammatory Bowel Diseases?
Is It Time For High Dose Influenza Vaccination In Inflammatory Bowel Diseases? Open
View article: 796 – Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study
796 – Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study Open
View article: Mo1828 – Histologic Disease Activity At Surgical Resection Margin is Associated with Early Endoscopic Crohn’s Disease Recurrence
Mo1828 – Histologic Disease Activity At Surgical Resection Margin is Associated with Early Endoscopic Crohn’s Disease Recurrence Open
View article: Sa1811 – Genotype and Posst-Operative Immunosuppression Impact Surgical Recurrence in Crohn's Disease
Sa1811 – Genotype and Posst-Operative Immunosuppression Impact Surgical Recurrence in Crohn's Disease Open
View article: Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort
Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort Open
Background and Aims Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn’s disease (CD) of …
View article: P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study
P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study Open
We aimed to describe the real-world effectiveness of tofacitinib in ulcerative colitis (UC). We analysed a retrospective, multi-centre cohort from six centres in the USA. UC patients started on tofacitinib (10 mg BID) for active disease we…